Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMA) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 29,620,000 shares, a growth of 34.9% from the December 15th total of 21,960,000 shares. Approximately 28.4% of the company’s shares are short sold. Based on an average daily volume of 4,700,000 shares, the days-to-cover ratio is currently 6.3 days.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. HC Wainwright reissued a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. Benchmark increased their price target on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, December 23rd. TD Cowen reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Finally, BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Down 1.1 %

Shares of HUMA stock traded down $0.05 during trading hours on Thursday, reaching $4.53. The company’s stock had a trading volume of 974,979 shares, compared to its average volume of 3,264,366. The firm’s 50 day simple moving average is $4.62 and its 200-day simple moving average is $5.67. The company has a market capitalization of $570.15 million, a price-to-earnings ratio of -3.38 and a beta of 1.32. Humacyte has a fifty-two week low of $2.48 and a fifty-two week high of $9.97.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the transaction, the chief executive officer now directly owns 2,419,712 shares of the company’s stock, valued at $10,743,521.28. This represents a 25.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Humacyte

Several hedge funds have recently modified their holdings of HUMA. Bank of New York Mellon Corp boosted its holdings in shares of Humacyte by 62.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock valued at $1,219,000 after acquiring an additional 97,931 shares in the last quarter. Rhumbline Advisers raised its position in shares of Humacyte by 87.8% in the 2nd quarter. Rhumbline Advisers now owns 110,919 shares of the company’s stock worth $532,000 after acquiring an additional 51,858 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after acquiring an additional 524,600 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Humacyte in the 2nd quarter worth about $110,000. Finally, Profund Advisors LLC bought a new position in shares of Humacyte in the 2nd quarter worth about $97,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.